Monoclonal Antibodies That Recognize the Human Type I Interferon Receptor and Block Interferon Signaling


Type I interferons play a critical role in both innate and adaptive immunity through the stimulation of the IFNAR1 which initiates interferon signaling in response to viral and bacterial infections. However, abnormal interferon signaling is associated with human diseases, such as lupus. The present invention discloses six hybridomas that produce mouse monoclonal antibodies specific for the extracellular domain of human IFNAR1. Two of the monoclonal antibodies are able to bind IFNAR1 and reduce interferon signaling. As such, they can be utilized as a research tool for studying the expression of IFNAR1 and the inhibition of IFNAR1 function in humans or possibly as therapeutic reagents for human diseases.

Potential Commercial Applications: Competitive Advantages:
  • Research reagents for studying the expression and signaling of IFNAR1.
  • A potential therapeutic reagent.
 
  • Specific for the extracellular domain of human IFNAR1. Can therefore specifically recognize receptor expressed on the cell surface.
  • Bind IFNAR1 and reduce interferon signaling


Inventors:
Sonja Best (NIAID)
Kirk Lubick (NIAID)
Shelly Robertson (NIAID)


Intellectual Property:
Research Material – Patent protection is not being pursued for this technology.

Publications:
Goldman LA, et al. PMID 10048764
Benoit P, et al. PMID 8423335

Collaboration Opportunity:

The National Institute of Allergy and Infectious Diseases (NIAID) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize human type I interferon receptor antibodies. For collaboration opportunities, please contact Alicia Evangelista at alicia.evangelista@nih.gov or 301-594-1673.


Licensing Contact:
Susan Ano , Ph.D.
NIH Office of Technology Transfer
Email: anos@mail.nih.gov
Phone: 301-435-5515

OTT Reference No: E-527-2013/0

Updated: Aug-22-2013